Clinical Trial Update: Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD [Phase 1]

View source ↗

Summary

Phase 1 trial of Soquelitinib in adults with moderate-to-severe atopic dermatitis shows safety and tolerability with preliminary signs of efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Soquelitinib

Snippet

Sponsor: Corvus Pharmaceuticals, Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED